Improving Surveillance for Hepatocellular Carcinoma in the UK

Activity: Participating in or organising an eventParticipation in workshop, seminar, course


Hepatocellular carcinoma is a major cause of cancer mortality in the UK. NICE guidelines recommend that people with cirrhosis should receive HCC surveillance, defined as an ultrasound scan of the liver every six months. The goal of surveillance is to detect HCC early when it is easier to treat. However, the delivery and implementation of surveillance in the UK (as in many other countries) is suboptimal and has been for many years. Indeed, only a minority of eligible patients receive adequate surveillance, and most people who develop HCC are diagnosed at advanced stages.
We will host a monothematic meeting on improving HCC surveillance, which will take place in Birmingham on April 22nd 2024. The meeting is being sponsored by NHS England and will showcase new ideas and developments for improving HCC surveillance in the UK. We will highlight key initiatives that are currently underway in the UK to increase early HCC detection. We will discuss the latest thinking on personalised surveillance and consider what relevance and application this has to HCC. We will also look at what new surveillance tests are on the horizon and how these innovations are likely to alter the surveillance landscape. Our meeting will feature a wide range of renowned speakers, researchers and opinion leaders in this field
Period22 Apr 2024
Event typeOther
LocationBirmingham, United KingdomShow on map